A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome

ConclusionLirilumab either as a single agent as well as used in combination with azacitidine has clinical activity in patients with MDS. Further studies are needed to confirm our findings.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research